Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


PhRMA Seeking Injunction Against 340B Orphan Drug Exclusion Rule

This article was originally published in The Pink Sheet Daily

Executive Summary

The trade group files a lawsuit seeking preliminary and permanent injunctions against implementation of a final rule that requires 340B discounts for the non-orphan uses of drugs with an orphan designation.

You may also be interested in...

340B Orphan Drug Rule Overturned In Court, Putting Future Regs Into Question

A federal court rules in favor of the Pharmaceutical Research and Manufacturers of America in its lawsuit seeking injunction against the 340B discount program’s orphan drug rule. The rule “must be vacated” because HHS lacks the statutory authority to issue the rule, the judge says, giving rise to questions about how upcoming 340B regs will be affected.

340B Meets Part B: Payment Proposal Unites Big Pharma and Safety Net Providers

The annual hunt for “pay-fors” is on: Congress is looking for offsets to pay for the cost of reversing physician payment cuts under Medicare. One idea would be to allow Medicare Part B to capture the prices of the 340B discount program. Providers who use 340B hate the idea – and manufacturers do too.

PhRMA Sues FTC To Halt Rule On Drug Patent Licensing Deals

PhRMA says the reporting rule is discriminatory since it singles out one industry; the association brought four suits against government agencies in 2013.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts